Raymond James raised the firm’s price target on Boston Scientific to $94 from $91 and keeps a Strong Buy rating on the shares. The firm sees new drivers in the second half of 2024 that give it more confidence in its above-consensus view of Boston Scientific’s Electrophysiology Products business, which should drive upside to consensus estimates and reinforce Boston Scientific’s status as one of the fastest growing large cap healthcare names, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific obtains CE mark for ACURATE Prime Aortic Valve System
- Boston Scientific price target raised to $92 from $90 at Citi
- Boston Scientific price target raised to $86 from $78 at Barclays
- Jefferies healthcare analyst to hold an analyst/industry conference call